吗啡和血管紧张素Ⅱ对大鼠脑突触小体Ca~(2 )摄取的拮抗效应

行为实验已多次证明,脑室注射血管紧张素Ⅱ(AⅡ)可以对抗吗啡的镇痛作用,但机制不明。吗啡阻止神经末梢钙摄取被认为是其镇痛的机理之一,因此本工作研究了AⅡ和吗啡对大鼠脑突触小体~(45)Ca摄取的作用及相互关系。结果表明,吗啡(10~(-8)—10~(-6)mol/L)对~(45)Ca摄取有明显的抑制作用,10~(-7)mol/L时抑制41％(P<0.001),该效应可被吗啡受体阻断剂纳洛酮(10~(-6)mol/L)完全翻转。与吗啡的作用相反,AⅡ(10~(-8)—110~(-6)mol/L)可促进突触小体对~(45)Ca的摄取,10~(-7)mol/L时增加75％(P<0.001),该效应可被AⅡ受体阻断剂Saralasin(10~(-6)mol/L)完全翻转。将不同剂量的AⅡ(10~(-8)—10~(-6)mol/L)和10~(-8)mol/L吗啡与突触小体共同孵育,则吗啡抑制~(45)Ca摄取的作用被完全翻转。以上结果表明,AⅡ促进脑突触小体Ca~(2 )摄取,对抗了吗啡抑制Ca~(2 )摄取的作用,可能是AⅡ抗吗啡镇痛的机制之一。     

阿片肽及有关因素在脊髓损伤中的作用

本文主要述及:(1)脊髓损伤后局部组织中的强啡肽含量升高,免疫活性增强,κ受体结合力也增强。纳洛酮可明显减轻脊髓外伤造成的后果,促进神经功能的恢复;(2)预先给予κ受体特异性拮抗剂nor-BNI可显著减轻鞘内给予强啡肽A(1—17)所致的损伤;缺乏阿片样活性的强啡肽A(2—17)致脊髓损伤的剂量大于强啡肽A(1—17),且其效应不为nor-BNI所拮抗;(3)预先给予抗强啡肽A的抗血清,显著改善脊髓外伤的程度,促进功能恢复;(4)预先给予强啡肽可加重脊髓外伤,κ-受体拮抗剂可减轻之;(5)NMDA受体和Ca~(2+)在强啡肽致脊髓损伤中可能起着重要作用。以上资料说明强啡肽在脊髓损伤中有重要作用。     

血管紧张素Ⅱ和阿片肽对Fos蛋白表达的影响

利用抗体免疫沉淀技术研究了血管紧张素Ⅱ(AⅡ),δ受体激动剂(DPDPE)和к受体激动剂(NDAP)对大鼠脑组织c-fos原癌基因表达的影响.结果表明,0.1μmol/LAⅡ可显著刺激脑组织中Fos蛋白的表达,0.1μmol/L DPDPE和0.1μmol/L NDAP对Fos蛋白的表达亦有一定的诱导作用.AⅡ与DPDPE或NDAP共同处理组织,Fos蛋白表达水平低于AⅡ单独诱导的水平.结果表明阿片肽可抑制AⅡ对Fos蛋白表达的作用.     

血管紧张素Ⅱ增加新生鼠脑细胞胞浆Ca~(2+)浓度

本文应用荧光钙测定技术观察了血管紧张素Ⅱ(AⅡ)对新生Wistar鼠脑细胞胞浆Ca~(2+)浓度([Ca~(2+)]_i)的影响。结果表明:血管紧张素Ⅱ在1nmol/L—1μmol/L浓度下可诱导新生鼠脑细胞[Ca~(2+)]_i增加,具量效关系。在无外Ca~(2+)存在对,其增加幅度有所减少。上述效应可被血管紧张素Ⅱ拮抗剂Saralasin所阻断,并呈剂量依赖关系。上述结果提示,血管紧张素Ⅱ可激活血管紧张素AⅡ受体,增加脑细胞[Ca~(2+)]_i,该效应通过细胞内Ca~(2+)释放和细胞外Ca~(2+)内流两条适径实现,前者的作用是主要的。     

牛脑Ca~(2+)/CaM依赖性蛋白激酶Ⅱ的纯化和鉴定

通过一系列层析法,首次从牛脑纯化得到胶凝电泳匀一的Ca~(2+)/CaM PKⅡ。凝胶过滤法测定全酶分子量为550kD,SDS-PAGE法测定亚基分子量为55kD,推测牛脑Ca~(2+)/CaM PK Ⅱ由十个相同的亚基组成。该酶活性绝对依赖于Ca~(2+)和CaM,以63kD PDE同工酶为底物,其AC_(50)分别为0.85μmol/L和0.18μmol/L;以酪蛋白为底物,其AC_(50)分别为0.22μmol/L和0.06μmol/L。牛脑Ca~(2+)/CaM PK Ⅱ旣能催化63kD PDE同工酶等多种蛋白或酶磷酸化,又能进行自身磷酸化。该酶催化63kD PDE同工酶最大磷酸参入量为1mol/mol亚基。磷酸化型63kD PDE同工酶的Ca~(2+)的AC_(50)高于非磷酸化型。     

NaCl(2 mol/L)处理PSⅡ颗粒的Ca~(2+)重结合

回加Ca~(2+)对 NaCl(2 mol/L)处理菠菜PSⅡ颗粒放氧活性的作用表现出有两种K_m值分别为 0.021和 0.545 mmol/L的高亲和与低亲和的Ca~(2+)重结合过程。高浓度NaCl和低 pH(3.0)处理去Ca的 PSⅡ颗粒的光抑制放氧活性半衰期(t_(1/2))明显减小。重结合Ca~(2+后,虽然大部办丧失的放氧活性可恢复,但PSⅡ颗粒放氧活性对光抑制的敏感性却并不随之恢复,t_(1/2)无明显改变。显然,重组Ca~(2+)的结合状态和作用与PSⅡ颗粒原有的结合Ca不完全相同。     

八肽胆囊收缩素对抗mu和Kappa型受体介导的镇痛作用

以往的资料表明,八肽胆襄收缩素(CCK-8)能对抗阿片镇痛,本实验进一步分析 CCK-8对抗哪一类型阿片受体激动剂的镇痛作用。给大鼠脊髓蛛网膜下腔(I.T.)注射 CCK-8(剂量4ng到1.0μg)既不产生痛敏也不产生镇痛。I.T.注射特异性的μ受体激动剂 PL01710 ng 或 k 受体激动剂 NDA P500 ng 引起的镇痛作用可被注射 CCK-8 4ng 所对抗。而L.T.注射δ受体激动剂 DPDPE(6.5,13.0和26.Oμg)引起的镇痛作用不能被 CCK-8(4ng,40ng I.T.)所对抗。但 CCK-8对抗 PL017和 NDAP 镇痛的作用可被 I.T.CCK 受体拮抗剂 proglumide(3μg)所翻转。以上结果表明,I.T.注射 CCK-8可有效地对抗μ和 k 受体介导的镇痛,并且这种对抗作用是经 CCK 受体介导而实现的。     

低频和高频电针镇痛由脊髓水平不同类型的阿片受体介导:交叉耐受试验

以往的工作表明,给大鼠低频或高频电针在脊髓中分别释放出脑啡肽或强啡肽,产生镇痛效果。本工作用交叉耐受方法对此进行检验并进一步分析其受体机制。结果表明:(1) 给大鼠2Hz电针电针6h,镇痛作用逐渐降低导致耐受后,100Hz电针仍有明显的镇痛作用;100Hz耐受后,2Hz电针仍有效。说明低频和高频电针镇痛之间无明显的交叉耐受。(2) 100Hz电针耐受后,k激动剂强啡肽A(1—13)的脊髓镇痛作用明显减弱,而δ激动剂[(?)]enkephalin(DPDPE)仍保持明显的镇痛作用。(3) 2Hz电针耐受后,DPDPE的镇痛效果显著降低,而强啡肽A(1—13)的镇痛作用不受影响。根据以上的交叉耐受实验结果可以认为,脊髓中δ型阿片受体参与2Hz电针镇痛,而κ型阿片受体参与100Hz电针镇痛。     

八肽胆囊收缩素对大鼠颈动脉窦压力感受器反射的抑制作用

在36只隔离灌流颈动脉窦区的麻醉大鼠上,观察了八肽胆囊收缩素(cholecystokinin octapepide,CCK-8)对颈动脉窦压力感受器反射的影响。其结果如下：(1)以CCK-8(0．1、0．5、1．0μmol／L)隔离灌流颈动脉窦区时,压力感受器机能曲线向右上方移位,曲线最大斜率(peak slope,PS)减小,反射性血压下降幅度(reflex decrease,RD)减少,阈压(threshold pressure,TP)和饱和压(saturation pressure,SP)均增高。其中RD、PS和TP呈明显的剂量依赖性;(2)用CCK-8的非特异性受体拮抗剂丙谷胺(100μmol／L)预处理后,能明显减弱CCK-8(0．50mol/L)对压力感受器反射的抑制;(3)预先灌流一氧化氮合酶(nitric oxide synthase,NOS)阻断剂(L-NAME,100μmol／L),不能阻断CCK-8(0．5μmol/L)对压力感受器反射的影响;(4)用Ca^2 通道激动剂Bay K 8644(500nmol／L)预处理后,也能明显减弱CCK-8(0．5μmol／L)对压力感受器反射的抑制作用。以上结果提示,CCK-8是通过作用于颈动脉窦压力感受器神经元末梢上的受体而起到抑制作用的,其机制可能为抑制了牵张敏感性通道,致使Ca^2 离子内流减少,而与内皮细胞释放NO无关。     

重金属离子对猪红细胞膜Ca~(2+)-ATP酶的作用

猪红细胞膜Ca~(2+)-ATP酶是一种钙调蛋白(CaM)依赖酶,其活力又依赖巯基的完整性。实验应用Ca~(2+)-ATP酶这一模型体系观察到重金属离子,Pb~(2+)、Cd~(2+)和Hg~(2+)都能替代Ca~(2+),激活CaM,从而激活Ca~(2+)-ATP酶;其最大刺激活力分别为85％、80％和30％,半刺激浓度分别为32、27和0.7μmol/L。当三种重金属离子的浓度增加时,则与Ca~(2+)-ATP酶的巯基结合,抑制酶的活力,Pb2~(2+)、Cd~(2+)和Hg~(2+)的半抑制浓度分别为370、440和2μmol/L。抑制作用为渐进性过程,而刺激作用为即时效应。抑制作用可为巯基化物,特别是二巯基化物所逆转。研究结果提示,CaM可能是重金属中毒最初作用的靶分子,而重金属中毒不仅使CaM“开关”失灵,还可能导致细胞内Ca~(2+)的调节全面失控。     

Modification by Cholecystokinin Octapeptide of the Binding ofμ-, δ-, and K-Opioid Receptors

Previous study has shown that cholecystokinin (CCK) octapeptide (CCK-8) suppressed the binding of opioid receptors to the universal opioid agonist [3H]etorphine. In the present study, highly selective tritium-labeled agonists for the mu-[(tryrosyl-3,5-3H][D-Ala2,MePhe4,Gly-ol5]enkephalin ([3H]DAGO], delta- ([tyrosyl-3,5-3H][D-Pen2,5]enkephalin ([3H]DPDPE], and kappa- ([3H]U69,593) opioid receptors were used to clarify which type(s) of opioid receptor in rat brain homogenates is suppressed by CCK-8. In the competition experiments, CCK-8 suppressed the binding of [3H]DAGO and [3H]U69,593 but not that of [3H]DPDPE to the respective opioid receptor. This effect was blocked by the CCK antagonist proglumide at 1 mumol/L. In the saturation experiments, CCK-8 at concentrations of 0.1 nmol/L to 1 mumol/L decreased the Bmax of [3H]DAGO binding sites without affecting the KD; on the other hand, CCK-8 increased the KD of [3H]U69,593 binding without changing the Bmax. The results suggest that CCK-8 inhibits the binding of mu- and kappa-opioid receptors via the activation of CCK receptors.     

Mobilization of calcium from intracellular stores as one of the mechanisms underlying the antiopioid effect of cholecystokinin octapeptide.

In enzymatically dissociated brain cells prepared from neonatal rats, KCl produced a significant increase in [Ca2+]i and this increase could be prevented by verapamil or nifedipine, known to block voltage-sensitive calcium channels. The opioid receptor agonists ohmefentanyl (OMF, mu agonist), [D-Pen2,D-Pen5]enkephalin (DPDPE, delta agonist), and 66A-078 (kappa agonist) produced a marked suppression of the Ca2+ influx induced by high K+ depolarization. The suppressive effect of OMF, DPDPE, and 66A-078 on the high K(+)-induced increase in [Ca2+]i was markedly reversed by their respective antagonists beta-funaltrexamine (beta-FNA), ICI174864, and nor-binaltorphimine (nor-BNI). Cholecystokinin octapeptide (CCK-8), at concentrations of 0.3, 3.0, and 30 nM, dose-dependently mobilized Ca2+ from intracellular stores. While CCK-8 30 nM did not affect significantly the increase of [Ca2+]i following high K+, it did reverse the suppression of the high K(+)-induced increase in [Ca2+]i by the mu agonist OMF and the kappa agonist 66A-078, but not that by the delta agonist DPDPE. The results suggested that while opioid ligands suppress [Ca2+]i by blocking voltage-operated Ca2+ influx, the antiopioid effect of CCK-8 seems to be operated via mobilization of Ca2+ from intracellular stores.     

吗啡和血管紧张素II对大鼠脑突触小体Ca^2＋摄取的拮抗效应

Behavioral observations have repeatedly shown that the analgesic effect of morphine can be antagonized by intracerebroventricular injection of angiotensin I (A I), although mechanisms underlying the action were obscure. Since a prevention of Ca2+ uptake into the nerve terminals was considered as one of the mechanisms for morphine analgesia, we examined the effect of A I and morphine on the 45Ca uptake by rat brain synaptosomal preparations. Morphine of 10(-8)-10(-6) mol/L produced a dose-related suppression on synaptosomal 45Ca uptake, which was completely reversed by the opioid antagonist naloxone of 10(-6) mol/L. A I of 10(-8)-10(-6) mol/L, on the contrary, enhanced 45Ca uptake. This effect was totally abolished by saralasin, a A I antagonist, at 10(-6) mol/L. When synaptosomal preparations were incubated in a mixture of morphine (10(-6) mol/L) and A I (10(-8)-10(-6) mol/L), the effect of morphine was almost completely reversed. The results suggest that the distinct effect of A I may account for, at least in part, the antagonistic effect of A I on morphine analgesia.     

CCK－8和NDAP对大鼠脑和脊髓组织c－fos表达的影响

为探讨八肽胆囊收缩素（ＣＣｋ－８）和阿片肽相互作用的分子机理,利用抗体免疫沉淀技术研究了ＣＣＫ－８与ＮＤＡＰ（ｋ阿片受体激动剂）对大鼠脑（去皮层和小脑）和脊髓背柱组织Ｆｏｓ蛋白的影响。结果表明,０．１μｍｏｌ／ＬＣＣＫ－８可显著刺激脑和脊髓组织中Ｆｏｓ蛋白增加（分别是对照组的３．８倍和３．６倍）。相同浓度的ＮＤＡＰ对Ｆｏｓ蛋白的生成亦有一定的诱导作用,分别是对照组的２．７倍和２．６倍。ＣＣＫ－８和ＮＤＡＰ共同处理组织,Ｆｏｓ蛋白生成水平相似（脑）或高于（脊髓）ＣＣＫ~－８单独诱导的水平。结果表明,ＣＣＫ－８和ＮＤＡＰ均可直接诱导大鼠脑和脊髓组织ｃ－ｆｏｓ的表达,它们对ｃ－ｆｏｓ表达的相互作用在脑和脊髓中呈现不同的模式。     

八肽胆囊收缩素对抗阿片肽的中枢性降血压作用

过去的工作已经证明八肽胆囊收缩素(CCK-8)能够对抗阿片肽的镇痛作用,本工作探讨CCK-8是否能够对抗阿片肽的心血管抑制作用。给戊巴比妥钠麻醉大鼠脊髓蛛网膜下腔(ith)注射 CCK-8可以对抗 ith 注射 mu(μ)型阿片受体激动剂[NMePhe~3,D-Pro~4]Morphiceptin(PL017)(5μg)、delta(δ)型受体激动剂[D-Ala~2,D-Leu~5]Enkephalin(DADLE)(25μg)和 Kappa(K)型受体激动剂[N-Me Tyr,N-Me Arg~7,D-Leu~8]Dynorphin 1-8 ethyla-mide(66A-078)(1μg)引起的降低血压和减慢心率作用。在 MAP 的表现上,CCK-8的拮抗作用(10μg及以下剂量)具有量-效关系,并可被 CCK 受体阻断剂丙谷胺(Proglumide)(100μg)翻转。在 HR 的表现上,上述剂量的 CCK-8也显示了一定的拮抗作用,但量-效关系不如 MAP 表现得明显。单纯将 CCK-8或 Proglumide ith 注射,可见大剂量(50μg)CCK-8可以引起明显的降血压作用和短时的降心率作用,小剂量(0.05μg)CCK-8则表现出明显的降心率作用;ith 注射 Proglumide 100μg,30 min 后也表现出减慢心率的作用。以上结果提示:在脊髓水平,一定剂量范围内的 CCK-8能够对抗阿片肽的心血管抑制效应,此对抗作用是通过 CCK 受体实现的。本工作的结果支持关于 CCK-8是一种抗阿片物质的设想。     

强啡肽对脊髓原生型与诱生型一氧化氮合成酶活性,分布和基因表达的影响

蛛网膜下腔注射强啡肽Ａ１－１７引起剂量依赖性后肢和尾部瘫痪及甩尾甩足抑制。脊髓背角（侧）ＮＭＤＡ受体和ＮＯＳ／ＮＯ功能活性下降可能与Ｄｙｎ镇痛作用有关,脊髓腹角（）ＮＭＤＡ受体－Ｃａ＾２＋－ＮＯＳ／ＮＯ通路过度激活及ｃ－ｆｏｓ高表达可能与Ｄｙｎ致脊髓损伤作用有关。     

Partial depletion of endogenous zinc level by (D-Pen2, D-Pen5)enkephalin in the rat brain.

The effects of the potent delta opioid agonist (D-Pen2, D-Pen5)enkephalin (DPDPE) were studied on the endogenous levels and regional distribution of Zn2+ in rat central nervous system by means of flame atomic absorption spectrophotometry. The olfactory bulb exhibited the highest Zn2+ level, followed by the frontal and parietal cortices, striatum and hippocampus; the lowest ion levels were found in the medulla and thoracic spinal cord. Intracerebroventricular administration of DPDPE resulted in significant, time- and dose-dependent decreases in endogenous Zn2+ contents in the parietal cortex, hippocampus and striatum. The action of DPDPE was antagonized by a 30 min naloxone pretreatment. Naloxone alone was without effect in eliciting these responses. Thus, delta opioid receptors may regulate or modulate endogenous Zn2+ levels in the rat brain.     

Cross-tolerance studies in the spinal cord of beta-FNA-treated mice provides further evidence for delta opioid receptor subtypes.

In this study we investigated the development of cross-tolerance among intrathecally (i.t.)- administered mu and delta opioid receptor selective peptides in beta-funaltrexamine (beta-FNA)-treated mice. Tolerance to the antinociceptive effect of i.t. administered DPDPE was accomplished by administration of 16 nmol/mouse of DPDPE, i.t. 3 hr before testing in beta-FNA-treated mice (10 mumol/kg, s.c., 24 hr before the experiment). Cross-tolerance developed to the antinociceptive effect of i.t. administered DADLE but not to those of DSLET or DAMGO. DSLET (0.1 nmol/mouse i.t.) administration in beta-FNA-treated mice resulted in tolerance development to its antinociceptive effect. The same pretreatment resulted in a marginally significant increase in the antinociceptive ED50 value of DPDPE. There was no cross-tolerance to the antinociceptive effect of i.t. administered DADLE or DAMGO. These results provide further evidence for the existence of delta opioid receptor subtypes where DADLE and DPDPE interact with one site and DSLET with a different one.     

δ antagonist and κ agonist activity of naltriben: Evidence for differential κ interaction with the δ1 and δ2 opioid receptor subtypes

The selective δ₂ receptor antagonist Naltriben (NTB) has played an important role in the identification of subtypes of the δ opioid receptor, termed δ₁ and δ₂, and their role in antinociception. However, the majority of these studies have been conducted in the mouse. The present study determined the opioid receptor selectivity of subcutaneously (s.c.) administered NTB in the rat. Five minute pretreatment with 1 mg/kg s.c. NTB antagonized the increase in TFL produced by i.t. administration of equieffective doses of the δ₂ receptor agonist [D-Ala², Glu⁴]deltorphin (DELT) or the δ₁ receptor agonist [D-Pen², D-Pen⁵]enkephalin (DPDPE), but did not antagonize the μ receptor agonist [D-Ala², MePhe⁴, Gly-ol⁵]enkephalin (DAMGO). These data confirm previous reports that NTB is a selective δ opioid receptor antagonist. However, this dose of NTB antagonized DELT and DPDPE to an equivalent extent, suggesting that its selectivity for the δ₂ receptor is not maintained after s.c. administration in the rat. A lower dose of NTB (0.56 mg/kg s.c.) was ineffective. When the dose of NTB was increased to 3 mg/kg s.c. the antagonism of DELT and of DPDPE was unexpectedly lost. Pretreatment with the κ receptor antagonist nor-binaltorphimine (nor-BNI) partially restored the antagonism of DELT, but not DPDPE by this dose of NTB and did not modify the antagonism of DAMGO by NTB. These data suggest that high doses of NTB have κ receptor agonist-like activity and support the proposal that κ opioid agonists diminish the actions of δ receptor antagonists. They also suggest that nor-BNI-sensitive κ opioid receptors interact with δ₂, but not δ₁ opioid receptors in the spinal cord.